FS222 First in Human Study in Patients With Advanced Malignancies

Official title

A Phase 1, Open-Label, First-in-Human Study to Evaluate the Safety and Anti-tumour Activity of FS222, a CD137/PD-L1 Bispecific Antibody, in Subjects With Advanced Malignancies

Overview

This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS222 in participants with advanced tumours. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.

Interventions

• Drug FS222
  Dosing of participants will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) until disease progression or unacceptable toxicity.

Primary outcome measures

• Presence of adverse events (AEs) and serious adverse events (SAEs) [Time frame: 15 months]
• Determination of a maximum tolerated dose (MTD) by evaluation of DLTs [Time frame: 28 days]
• Determination of a recommended Phase 2 dose (RP2D) by evaluation of DLTs [Time frame: 28 days]

Eligibility criteria

Inclusion criteria

• Age ≥18 years.
• Participants with histologically or cytologically confirmed, locally advanced, unresectable or metastatic solid tumours for whom standard therapy has proven to be ineffective, intolerable or is considered inappropriate. This criterion does not apply to the PK/PD expansion cohort, where tumour-specific criteria will apply instead.
• No more than 1 line of prior therapy with ICB treatment. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
• Participants who have received prior ICB, or any concurrent chemotherapy, radiotherapy, investigational, biologic or hormonal therapy for cancer treatment may be eligible for enrolment following a washout period.
• Participants who have received prior anti-PD-L1 therapy are eligible if PD-L1 therapy was discontinued ≥6 months prior to entry into the study.
• Participants who have failed a prior ICB regimen should document it.
• Measurable disease. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
• Eastern Cooperative Oncology Group Performance Status ≤1.
• The participant agrees to undergo a mandatory pre-treatment and on-treatment biopsy of the tumour. Certain exceptions apply.
• Highly effective contraception.
• Willing and able to provide written informed consent.

Exclusion criteria

• Participants with clinically relevant COVID-19 disease risk will be excluded from enrolment during the COVID-19 pandemic.
• Concurrent enrolment in another clinical study with the exception of non-interventional/observational studies or the follow-up period of an interventional study.
• Prior treatment with CD137 agonist mAb or other experimental agonists.
• For participants who have received prior ICB, participants must not have received more than 1 line of prior treatment with ICB(s). Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
• Participants with active autoimmune disease.
• Receipt of any live virus vaccine within 30 days prior to the first dose of study drug.
• Receipt of a live attenuated vaccine within 30 days prior to the first dose of study drug.
• History of uncontrolled intercurrent illness.
• Psychological, familial, sociological or geographical conditions that do not permit compliance with the protocol.
• Judgment by the investigator that the participant is unsuitable to participate in the study, and the participant is unlikely to comply with study procedures, restrictions and requirements.
• Significant laboratory abnormalities.
• Known infections.
• Uncontrolled CNS metastases, primary CNS tumours with CNS metastases as only measurable disease. Exceptions as defined in protocol for PK/PD expansion cohorts will apply.
• Prior history of any Grade ≥3 irAE that has not improved to Grade ≤1, except for endocrine deficiencies that are managed by HRT; significant treatment-related cytokine release syndrome; systemic inflammatory response syndrome.
• Current use of immunosuppressive agents, prior organ transplantation requiring immunosuppression, hypersensitivity or intolerance to mAb or their excipients, or persisting toxicity related to prior therapy of Grade >1 NCI CTCAE Version 5.0 .

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Spain · 12 centers

• Clinica Universidad Navarra — Pamplona
• NEXT - Hospital Quironsalud Barcelona — Barcelona
• Hospital Universitari Vall D'Hebron — Barcelona
• Hospital Clinic de Barcelona — Barcelona
• Institut Catala d'Oncologia de Badalona — Barcelona
• Complejo Hospitalario Universitario Insular-Materno Infantil — Las Palmas de Gran Canaria
• Instituto de Investigación Sanitaria Fundación Jimenez Díaz — Madrid
• Hospital Universitario 12 De Octubre — Madrid
• … and 4 more centers

Australia · 2 centers

• Calvary Mater Newcastle — Waratah
• One Clinical Research Perth — Perth

Poland · 2 centers

• Centrum Medyczne Poznan - PRATIA - PPDS — Poznan
• MCM Krakow - PRATIA - PPDS — Krakow

Romania · 2 centers

• Prof. Dr. Alexandru Trestioreanu Oncologic Institute — Bucharest
• Prof Dr I Chiricuta Institute of Oncology — Cluj-Napoca

Georgia · 1 center

• Arensia Exploratory Medicine, LLC — Tbilisi

Germany · 1 center

• SLK Kliniken Heilbronn GmbH — Heilbronn

Netherlands · 1 center

• Radboud Universitair Medisch Centrum — Nijmegen

Identifiers

NCT: NCT04740424 · FS222-19101

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗